Grant: Engage Grants Program
University of British Columbia
$25,000.00
Novel nanoparticle-antibody conjugates for biotechnology applications
EF 2015-16
Résumé
The convergence of nanotechnology and biotechnology can lead to new and improved methods for biomedical
research and development, which will ultimately improve health care in Canada and worldwide. For example,
nanoparticles composed of gold, semiconductors, and magnetic materials such as iron oxide have unique
properties that can benefit diagnostic tests for molecular markers of disease, or the isolation of specific cell
types for study. Vancouver-based STEMCELL Technologies Inc. has a portfolio of iron oxide nanoparticle and
antibody products that can be used for these applications. These products have been enabled by iron oxide
nanoparticles and a patented ""tetrameric antibody complex (TAC)"" method of linking the nanoparticles with
antibodies. Many other types of nanoparticles are useful for a range of other biological applications, but have
not be utilized with the TAC method. We propose to collaborate with STEMCELL Technologies to adapt their
TAC methodology to gold and semiconductor nanoparticles using simple, modular, and reliable chemistry. The
antibody-nanoparticle conjugates will then be physically characterized and validated in biochemical assays.
This project will yield new methods from preparing biologically functional nanoparticles, support the training
of highly qualified personnel with skills valued by local scientific industry, enhance the technology and
(potentially) product portfolio of STEM CELL Technologies, and lead to future collaboration on the
development of novel biomedical methods and technologies.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
488712-2015
Name nom
Algar, Russ
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Novel nanoparticle-antibody conjugates for biotechnology applications
Keyword
NSERC
Application summary
The convergence of nanotechnology and biotechnology can lead to new and improved methods for biomedical
research and development, which will ultimately improve health care in Canada and worldwide. For example,
nanoparticles composed of gold, semiconductors, and magnetic materials such as iron oxide have unique
properties that can benefit diagnostic tests for molecular markers of disease, or the isolation of specific cell
types for study. Vancouver-based STEMCELL Technologies Inc. has a portfolio of iron oxide nanoparticle and
antibody products that can be used for these applications. These products have been enabled by iron oxide
nanoparticles and a patented ""tetrameric antibody complex (TAC)"" method of linking the nanoparticles with
antibodies. Many other types of nanoparticles are useful for a range of other biological applications, but have
not be utilized with the TAC method. We propose to collaborate with STEMCELL Technologies to adapt their
TAC methodology to gold and semiconductor nanoparticles using simple, modular, and reliable chemistry. The
antibody-nanoparticle conjugates will then be physically characterized and validated in biochemical assays.
This project will yield new methods from preparing biologically functional nanoparticles, support the training
of highly qualified personnel with skills valued by local scientific industry, enhance the technology and
(potentially) product portfolio of STEM CELL Technologies, and lead to future collaboration on the
development of novel biomedical methods and technologies.